|
|
|
|
|
|
|
|
|
|
|
|
|
10.11.25 - 07:33
|
QIAGEN präsentiert QIAsymphony Connect und zeigt neue Innovationen in der Präzisionsonkologie auf der AMP 2025 (Business Wire)
|
|
|
QIAsymphony Connect, die neue Generation der Automationsplattform zur Aufreinigung von Nukleinsäuren, wird auf der AMP 2025 vorgestellt, womit eine Early-Access-Phase vor der vollständigen Markteinführung Mitte 2026 beginnt
QIAGEN präsentiert Sample-to-Insight-Workflows für das umfassende Genom-Profiling (CGP, Comprehensive Genomic Profiling) auf Basis der Trinity™-Technologie von Element Biosciences
Partnerschaft mit Myriad Genetics Inc. zur Entwicklung eines Tests für homologe Rekombinationsdefizienz (HRD) für den Einsatz in der Krebsdiagnostik
GERMANTOWN, Md. & VENLO, Niederlande--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Einführung von QIAsymphony Connect, der neusten Generation von QIAGENs weit verbreiteter Automationsplattform zur Aufreinigung von Nukleinsäuren, auf der Jahreskonferenz der AMP (Association for Molecular Pathology) bekannt gegeben, die vom 11. bis 15. November in Boston stattfindet.
Die erste öffentliche Präsentation von QIAsy...
|
|
|
10.11.25 - 07:33
|
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025 (Business Wire)
|
|
|
QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026
QIAGEN showcases Sample to Insight workflows for comprehensive genomic profiling (CGP) based on Element Biosciences Trinity™ technology
Partnership with Myriad Genetics Inc. to highlight development of a homologous recombination deficiency (HRD) assay for use in cancer profiling
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--$QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN's widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston.
The first public introduction of QIAsymphony Connect builds on more than 3,000 cumulative placements at the end of 2024 of the first-generation version, with the new generation designed to su...
|
|
|
|
|
|
|
|
|
30.10.25 - 13:51
|
Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer (Business Wire)
|
|
|
LANSING, Mich.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year.
Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion North American business. Prior to that, Riggsbee spent nearly a decade as Chief Financial Officer at Myriad Genetics, where he led the company's finance, accounting, and investor relations functions and played a key role in expanding the company's portfolio and partnerships, as well as ...
|
|
|
|
|
|
|
|
|
|
|
23.09.25 - 14:03
|
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy (GlobeNewswire EN)
|
|
|
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS' broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
